CAGE Bio Inc.

10 clinical trials · Sponsor

Record	Firm	Date
A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo (NCT07357870)	CAGE Bio Inc.	2025-07-25
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis (NCT06923228)	CAGE Bio Inc.	2025-04-21
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis (NCT06810050)	CAGE Bio Inc.	2024-12-18
Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis (NCT05487963)	CAGE Bio Inc.	2022-11-09
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection (NCT05202366)	CAGE Bio Inc.	2022-02-08
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea (NCT04886739)	CAGE Bio Inc.	2021-05-07
Clinical Evaluation of the Residual Antimicrobial Activity (NCT04495920)	CAGE Bio Inc.	2020-06-16
CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes (NCT04508205)	CAGE Bio Inc.	2018-10-26
CGB-400 for the Reduction of Facial Redness (NCT04508660)	CAGE Bio Inc.	2018-10-26

Every clearance here is in the API, with alerts when new ones post.